Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 16, 2023 - Issue
Submit an article Journal homepage
310
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study

Nan Su1 Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China- Japan Friendship Hospital, Beijing, People’s Republic of China;2 National Center of Respiratory Medicine, Beijing, People’s Republic of ChinaView further author information
,
Lili Zhi3 Department of Allergy, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Shandong Institute of Respiratory Diseases, Jinan, People’s Republic of ChinaView further author information
,
Fengxia Liu4 Department of Allergy, Weifang People’s Hospital, Weifang, Shandong, People’s Republic of ChinaView further author information
,
Yongsheng Wang5 Department of Pulmonary and Critical Care Medicine, Chengdu First People’s Hospital, Chengdu, People’s Republic of ChinaView further author information
,
Qingling Zhang6 Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Xiansheng Liu7 Department of Pulmonary and Critical Care Medicine, Shanxi Bethune Hospital, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-9598-5054View further author information
ORCID Icon,
Xueyan Wang8 Allergy Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Guodong Hao9 Department of Allergy, Tangshan Gongren Hospital, Tangshan, Hebei, People’s Republic of ChinaView further author information
,
Xiuqin Zhang10 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, People’s Republic of ChinaView further author information
,
Qiang Hu11 Department of Pulmonary and Critical Care Medicine, Panzhihua Integrated Chinese and Western Medicine Hospital, Panzhihua, Sichuan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0009-0008-6980-7407View further author information
ORCID Icon,
Monica Ligueros-Saylan12 Respiratory Clinical/Medical 2, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Alkaz Uddin13 Analytics - Global Health DU, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Jing Yang14 Neuroscience & Respiratory Development Unit, Beijing Novartis Pharma. Co. Ltd, Beijing, People’s Republic of ChinaView further author information
,
Tiantian Liang15 Respiratory Clinical Development, China Novartis Institutes for BioMedical Research Co., Ltd, Beijing, People’s Republic of ChinaView further author information
,
Liju Ding16 GCTM-Group-2, China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Runqin Li17 New Products, Beijing Novartis Pharma. Co. Ltd, Shanghai, People’s Republic of ChinaView further author information
&
Chen Wang1 Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China- Japan Friendship Hospital, Beijing, People’s Republic of China;2 National Center of Respiratory Medicine, Beijing, People’s Republic of China;18 National Clinical Research Center for Respiratory Diseases, Beijing, People's Republic of China;19 Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China;20 Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China;21 Department of Respiratory Medicine, Capital Medical University, Beijing, People's Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 625-636 | Received 24 Feb 2023, Accepted 02 Jun 2023, Published online: 19 Jun 2023

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Corrado Pelaia, Antonio Giacalone, Gianluca Ippolito, Daniela Pastore, Angelantonio Maglio, Giovanna Lucia Piazzetta, Nadia Lobello, Nicola Lombardo, Alessandro Vatrella & Girolamo Pelaia. (2024) Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?. Pragmatic and Observational Research 15, pages 45-51.
Read now

Articles from other publishers (3)

V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Victor Gonzalez-Uribe, Sergio J. Romero-Tapia & Jose A. Castro-Rodriguez. (2023) Asthma Phenotypes in the Era of Personalized Medicine. Journal of Clinical Medicine 12:19, pages 6207.
Crossref
Francesca Galletta, Lucia Caminiti, Cecilia Lugarà, Simone Foti Randazzese, Paolo Barraco, Federica D’Amico, Pierangela Irrera, Giuseppe Crisafulli & Sara Manti. (2023) Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life. Journal of Personalized Medicine 13:7, pages 1068.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.